James A. Monn

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Sandeep T. Patil, Lu Zhang, Ferenc Martényi et al. · Nature Medicine · 2007 · 1K citations

Psychiatry, Psychotic Disorder, Medicine +12

Design, Synthesis, and Pharmacological Characterization of (+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY354740):  A Potent, Selective, and Orally Active Group 2 Metabotropic Glutamate Receptor Agonist Possessing Anticonvulsant and Anxiolytic Properties

James A. Monn, Matthew J. Valli, Steven M. Massey et al. · Journal of Medicinal Chemistry · 1997 · 392 citations

Pharmacological Characterization, Active Group 2, Psychotropic Medication +16

Synthesis, Pharmacological Characterization, and Molecular Modeling of Heterobicyclic Amino Acids Related to (+)-2-Aminobicyclo[3.1.0]hexane- 2,6-dicarboxylic Acid (LY354740):  Identification of Two New Potent, Selective, and Systemically Active Agonists for Group II Metabotropic Glutamate Receptors

James A. Monn, Matthew J. Valli, Steven M. Massey et al. · Journal of Medicinal Chemistry · 1999 · 286 citations · Full text

Active Agonists, Mglu Receptors, Pharmacotherapy +16

Anxiolytic and Side-Effect Profile of LY354740: A Potent, Highly Selective, Orally Active Agonist for Group II Metabotropic Glutamate Receptors

David R. Helton, J P Tizzano, James A. Monn et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 282 citations

LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors

Darryle D. Schoepp, Bryan G. Johnson, Rebecca A. Wright et al. · Neuropharmacology · 1997 · 225 citations

Functional Selectivity, Medicine, Neurotransmitter +5